The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...